Shah Capital Withdraws Proxy Campaign Against Re-Election of Directors at Novavax's 2024 Annual Meeting

Welcomes Recent Announcement by Novavax of Licensing Agreement with Sanofi Fellow Novavax Stockholders: As a long-term strategic investor, we have been engaging with the board of directors of Novavax (the "Board") for over a year in an attempt to unlock value on behalf of all of its shareholders, so it is heartening that our campaign has begun to deliver positive results. We long advocated for Novavax to explore potential strategic partnership opportunities and believe that the Company's recent announcement ...